Incyte
INCY
C$93.84
Share price
-2.49%
Change (1 day)
10.59%
Change (1 year)
Categories
Incyte (INCY) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : C$2.84 Billion
According to Incyte's latest financial reports the company's total liabilities are C$2.84 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Incyte - Total liabilities on balance sheet (from 2001 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | C$2.86 B | 35.67% |
| 2023-12-31 | C$2.11 B | 5.81% |
| 2022-12-31 | C$1.99 B | 34.62% |
| 2021-12-31 | C$1.48 B | 22.44% |
| 2020-12-31 | C$1.21 B | 11.92% |
| 2019-12-31 | C$1.08 B | 10.34% |
| 2018-12-31 | C$0.98 B | 16.06% |
| 2017-12-31 | C$0.84 B | -48.43% |
| 2016-12-31 | C$1.63 B | 41.22% |
| 2015-12-31 | C$1.16 B | 13.84% |
| 2014-12-31 | C$1.01 B | 16.36% |
| 2013-12-31 | C$0.87 B | 74.26% |
| 2012-12-31 | C$0.50 B | -11.15% |
| 2011-12-31 | C$0.56 B | -2.14% |
| 2010-12-31 | C$0.57 B | -32.58% |
| 2009-12-31 | C$0.85 B | 55.6% |
| 2008-12-31 | C$0.55 B | 26.9% |
| 2007-12-31 | C$0.43 B | -14.96% |
| 2006-12-31 | C$0.51 B | 11.44% |
| 2005-12-31 | C$0.45 B | -12.99% |
| 2004-12-31 | C$0.52 B | 80.24% |
| 2003-12-31 | C$0.29 B | -25.93% |
| 2002-12-31 | C$0.39 B | -6.7% |
| 2001-12-31 | C$0.42 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | C$113.77 B | 3,894.62% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | C$0.15 B | -94.72% | 🇺🇸 USA |
 Eli Lilly LLY | C$100.62 B | 3,432.62% | 🇺🇸 USA |
 Pfizer PFE | C$160.61 B | 5,538.92% | 🇺🇸 USA |
 Geron GERN | C$0.40 B | -85.87% | 🇺🇸 USA |
 Ardelyx ARDX | C$0.36 B | -87.29% | 🇺🇸 USA |
 Novartis NVS | C$84.12 B | 2,853.65% | 🇨🇭 Switzerland |
 AVEO Oncology
AVEO | C$99.04 M | -96.52% | 🇺🇸 USA |
 CTI BioPharma
CTIC | C$0.18 B | -93.39% | 🇺🇸 USA |